Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ImClone, Lilly license rights to Zymeworks' bi-specific antibody platform

Executive Summary

Zymeworks Inc. (antibodies and antibody-drug conjugates for cancer, autoimmune, and inflammatory diseases) granted Eli Lilly & Co. and its ImClone Systems Inc. division worldwide rights to use its Azymetric bi-specific antibody production platform to discover an undisclosed number of new therapies against Lilly’s cancer targets.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Bioinformatics
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies